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Abstract
Background: We have previously shown that Matrix metalloproteinase (MMP) -2 is a key-enzyme
in early trophoblast invasion and that Protein Kinase A (PKA) increases MMP-2 expression and
trophoblast invasion. The aim of this study was to examine MMP -2 regulation by PKA in invasive
trophoblasts: JAR choriocarcinoma cell-line and 6-8 w first trimester trophoblasts.
Methods: The effect of Forskolin (PKA) on MMP-2 expression was assessed by Northern Blot and
RT-PCR. Possible transcription factors binding to consensus MMP-2 promoter sequences in
response to Forskolin, were detected by EMSA binding assay and their expression assessed by
western blot analysis. Antisense transfection of relevant transcription factors was performed and
the inhibitory effect assessed on MMP-2 expression (RT-PCR), secretion (zymography) and
trophoblast invasiveness (transwell migration assay).
Results: We found that Forskolin increased MMP-2 mRNA in JAR cells within 24 hours, and
induced binding to p53, Ets, C/EBP and AP-2. Transcription factors Ets-2, phospho- p53, C/EBP
epsilon, C/EBP lambda and AP-2 alpha bound to their respective binding sequences in response to
Forskolin and the expressions of these transcription factors were all elevated in Forskolin- treated
cells. Inhibition of Ets-2 and p53 reduced MMP-2 expression, secretion and invasiveness of
Forskolin treated cells.
Conclusion: MMP-2 is regulated by PKA through several binding sites and transcription factors
including Ets-2, p53, C/EBP, C/EBP lambda and AP-2 alpha. Ets-2 and p53 mediate cAMP- induced
trophoblast invasiveness, through regulation of MMP-2.
Background
During implantation the trophoblast exhibit behavior
similar to tumor cells, including tissue invasiveness,
metastasis, loss of contact inhibition, escape from
immune surveillance and massive proliferation ability
[1]. However, in sharp contrast to aggressive tumors, tro-
phoblast invasion process is a spatial and temporal strictly
regulated process, controlled by multiple interactions
between cells and environment, mediated by several fac-
tors including growth factors, hormones and cytokines
[2,3].
Trophoblast are highly invasive due to the secretion of
extracellular proteases, like Matrix Metalloproteinases
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(MMPs), mediating degradation of the extracellular
matrix (ECM), and of their balancing inhibitors Tissue
inhibitors of Metalloproteinases (TIMPs) [4-6]. The two
gelatinases, MMP-2 and MMP-9, digest type IV collagen,
the main component of the basement membrane and are
therefore regarded as key enzymes in trophoblast invasion
[5,7-9]. MMP-2 and MMP-9 expression is differential dur-
ing the first trimester of pregnancy. MMP-2 production is
dominant until 8 weeks of gestation and then declining,
whereas MMP-9 production significantly increases from 8
weeks, causing a shift of dominant gelatinase from MMP-
2 to MMP-9 from 9 week of gestation [8,9]. The implanta-
tion process occurs by two waves of invasion by the tro-
phoblast, the first strictly controlled to the implantation
site and completed at 8 weeks of gestation, and the second
wave deep into the uterine wall at the end of first trimester
[10,11]. MMP-2 is likely to be the key-enzyme in the first
physiological invasion wave, whereas MMP-9 may be the
key-enzyme in the second invasion wave.
The JAR cell line, obtained from choriocarcinoma, is com-
prised of highly invasive trophoblast, expressing mainly
MMP-2 and to a much lesser extent MMP-9 [8,12,13]. JAR
cells were shown in our lab to resemble early 1st trimester
trophoblast in gelatinase profile and invasiveness, and
can therefore be used as a good model for studying early
invasive trophoblast regulation [8]. Several factors with
importance in embryo implantation act via cyclic adenos-
ine monophosphate (cAMP)-protein kinase A (PKA) sig-
nal transduction pathway, including human chorion
gonadotropin (hCG), the primary signal of an implanting
pregnancy [14,15]. hCG was found to increase collageno-
lytic activity, trophoblast invasion and migration [15-17],
and MMP-9 [18]. Forskolin is a prototypical stimulator of
the cAMP pathway by direct activation of adenylate
cyclase [19]. In a previous study, we showed that Forsko-
lin (PKA) induces MMP-2 and MMP-9 and trophoblast
invasiveness in both JAR cells and 1st trimester trophob-
lasts [8]. Forskolin has been used also in other studies to
induce invasion or invasion-related molecules [19,20].
Additionally, Forskolin/cAMP has been used to induce
syncytiotrophoblast formation [21,22]. The use of cell-
lines of different origin as well as primary or term tro-
phoblast may be the cause of these differential effects.
Most MMPs are regulated at the transcriptional level, by
several cytokines and growth factors, which influence
multiple signaling pathways [23]. The MMP gene pro-
moter contains several cis-regulatory elements, often act-
ing synergistically, with varying importance and effect,
depending upon cell-type and inducer [6]. The MMP -2
promoter lacks a typical TATA-box, but is not refractory to
modulations as previously thought [24,25]. The transcrip-
tional regulation on MMP-2 in trophoblasts is not yet
clear. The aim of this study was to investigate the tran-
scriptional regulation of MMP-2 in cAMP- activated inva-
sive trophoblast. Other MMP regulation levels include
mRNA stabilization, protein activation or inhibition, sur-
face localization and secretion; however these levels were
not part of the present study.
Methods
Cell culture
The JAR (Jar, HTB 144, ATCC) human choriocarcinoma
line was a generous gift from Pr. Hochberg, Hebrew Uni-
versity, Israel. JAR cells were cultured in M-199 medium
containing 10% Fetal Calf Serum (FCS) and penicillin/
streptomycin (all Beit-Ha'Emek, Israel) at 37°C in a
humidified, 5% CO2 atmosphere. After 24 h, medium was
changes to M-199 medium with 1.5% serum, in the pres-
ence or absence of Forskolin 10 μM (Sigma, ST Louis, MO,
USA).
Isolation and cultivation of human cytotrophoblast
Human trophoblast cells were obtained from legal abor-
tions (6 to 8 weeks), with the approval of the local ethical
committee (in compliance with the Helsinki Declaration)
and the consent of the participating patients. Trophoblast
cells were isolated according to a protocol generously pro-
vided by Desoye G, clinic of Obstetrics and Gynecology,
Austria. Briefly, placenta were washed in saline, then the
minced trophoblastic villi were digested by 0.25% trypsin
and DNase I (both Sigma, ST Louis, MO, USA), and CTB
separated from blood cells and decidua on a discontinu-
ous Percoll gradient (Sigma, ST Louis, MO, USA). Con-
taminating
leukocytes were removed by immunopurification with
anti- CD45RB (DAKO, Glostrup, Denmark) coupled to
magnetic particle. This method supplies a 95-98% purity
of trophoblast, including all trophoblast sub-groups [26].
Cells were cultured in M-199 medium supplemented with
1.5% FCS and 1% penicillin/streptomycin for the various
experiments.
Substrate-gel-electrophoresis (zymography)
Proteolytic activity of culture supernatants were detected
using gelatin-substrate gel electrophoresis (zymography).
Samples, normalized to cell count performed with XTT
Reagent kit (Beit-Ha'Emek, Israel), were diluted in sodium
dodecyl sulphate (SDS) sample buffer and electro-
phoresed through a 10% SDS-polyacrylamid gel contain-
ing 0.5% gelatin. Afterwards, gels were rinsed in 2.5%
Triton X-100 (Sigma, St. Louis, MO, USA) and incubated
for 24 h at 37°C in 0.2 mol/l NaCl, 5 mmol/l CaCl2, 0.2%
Brij 35 and 50 mmol/l Tris, pH 7.5. Gels were stained with
Coomassie Blue G in 30% methanol and 10% acetic acid.
Each gelatinase band was identified in accordance to theReproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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molecular weight and commercial standards (data not
shown). Bands on each gel were compared to their control
band and quantified with a densitometer system,
endowed with Bio-Capt and TINA software (Raytest,
Staubenhardt, Germany).
Matrigel invasion assay
Matrigel (1 mg/ml) (BD Biosciences, Franklin Lakes, NJ,
USA) diluted in serum free media was added to upper
chamber of 24-well transwell plate (8 μm pores, Corning,
MA, USA). 105 cells in 100 μl media were added to the
upper chamber, and 500 μl media added to the lower
chamber. 10 μM Forskolin was added to medium in upper
and lower wells and cells incubated at 37°C for 48-72
hours. Cells (105/well) seeded simultaneously in the same
media in a well without transwell, served as reference of
total seeded cells. After incubation non-invaded cells on
top of the transwell were scraped off with a cotton swab
and the amount of invaded cells in the lower well as well
as the amount of total seeded cells was evaluated with XTT
Reagent kit. The percent of invasion was calculated as:
Invasion was expressed as Invasion Index (Percent of con-
trol).
RNA extraction
Total cellular RNA was extracted using a total RNA isola-
tion kit EZ-RNA (Beit HaEmek, Israel) according to man-
ufacturer's instructions. RNA concentration was
determined spectro-photo-metrically.
Northern blot analysis
15 μg of total RNA was electrophoresed on a 1% denatur-
ating agarose gel and transferred to a nitrocellulose mem-
brane. The membrane was hybridized with 2 μg/lane
complimentary digoxigenin-labeled DNA probe for
MMP-2 or GAPDH (Biognostik, Göttingen, Germany)
using the digoxigenin (DIG) Easy Hyb system, according
to manufacturer's instructions (Roche, Basel, Switzer-
land). The probes were previously labeled with digoxi-
genin by terminal transferase labeling kit (Roche, Basel,
Switzerland). The membrane was then rinsed in 2× SSC/
SDS and in 0.1× SSC/SDS. Bands were detected with anti-
digoxigenin-AP antibody and the chemiluminescent sub-
strate CSPD (both Roche, Basel, Switzerland) on X-ray
film.
Reverse transcription-polymerase chain reaction (RT-
PCR)
First-strand cDNA was synthesized from 2-4 μg of total
RNA using 0.5 μg oligo (dt) primer, 1 mM dNTP, 15 Units
AMV reverse transcriptase (Promega, Mannheim, Ger-
many), 5 mM MgCl2 and buffer (10 mM Tris0Hcl, 50 mM
KCL, o.1% Triton x-100). RT-PCR was performed in a final
volume of 50 μl containing 10 μl cDNA, 10 mM dNTPs
(Promega, Mannheim, Germany), 1.5 U Taq polymerase
(Sigma, ST Louis, MO, USA), 50 pmol of each primer and
1× reaction buffer. Amplification parameters were 30
cycles as follows: denaturation, 30 sec at 94 °C, annealing,
60 sec at 58 °C, extension, 90 sec at 72 °C. MMP-2 primer
forward (F): ACCTGGATGCCGTCGTGGAC and reverse
(R): TGTGGCAGCACCAGGGCAGC, GAPDH primer F:
TGAACGGGAAGCTCACTGG and R: TCCACCACCCT-
GTTGCTGTA (IDT Inc., Hy-Labs, Rehovot, Israel). Ampli-
fication of GAPDH gene transcripts was performed
simultaneously to confirm RNA integrity, efficiency and
for quantification of cDNA. Negative control reactions
containing samples without cDNA or Taq enzyme were
used (data not shown). RT-PCR products were analyzed
by 2.5% agarose gel electrophoresis. Images were captured
with Polaroid (Hertfordshire, UK) film under UV light.
Products were quantified using a Densitometer system
endowed with TINA software (Raytest, Staubenhardt, Ger-
many).
Preparation of nuclear extract
JAR cells or 1st trimester trophoblasts were incubated in
serum-free medium for 24 hours, with or without 10 μM
Forskolin. Cells were lysed with swelling buffer (10 mM
Hepes, 10 mM KCL, 1 mM EDTA, 1 mM DTT, 1 mM
PMSF, 10 μg/μl Leupeptin, 50 μg/ml Aprotinin) for 15
min at 4°C, then 10% NP-40 was added for lysis and cells
centrifuged at 4°C for 3 min at 3000 RPM. The cytosol
protein extract was collected and the remaining pellet
resuspended in extraction buffer (20 mM Hepes, 200 mM
NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 10 μg/μl Leu-
peptin, 50 μg/ml Aprotinin), vortexed and kept at 4°C for
15 min, then centrifuged at 4°C for 5 min at 12000 RPM.
The protein concentration was determined with Bradford
reagent assay (Bio-Rad laboratories, Washington, DC).
Nuclear extract was assayed for the presence of transcrip-
tion factors, entering the nucleus in response to stimulus.
Electrophoretic mobility shift assay
Transcription factor activities were assessed by EMSA
using double-stranded oligonucleotide corresponding to
the consensus sequences of the MMP-2 promoter [25].
Oligonucleotides (Activator protein (AP)-1, AP-2, selec-
tive promoter factor (SP)-1, erythroblastosis virus E26
oncogene homolog (ETS), CCAAT-enhancer-binding pro-
tein (C/EBP), cAMP regulatory element binder (CREB),
protein 53 (p53) [Santa Cruz Biotech, California, USA,
(Table 1)] were labeled with digoxigenin (Roche, Basel,
Switzerland) using Terminal Transferase according to
manufacture's instructions in dig-labeling kit (Roche,
Basel, Switzerland). Binding reactions were conducted by
Absorbance of invaded cells Invasion index  ×= 100 (%).Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
Page 4 of 15
(page number not for citation purposes)
incubation of 6 μg of nuclear extract from JAR cells with
digoxigenin- labeled oligonucleotide probes at 30°C for
30 min. in binding buffer containing 15 mM Hepes, 90
mM KCL, 6% glycerol, 3 mM DTT, 0.5 μg Poly [d(I-C)]
and 0.4 ng oligonucleotide. Subsequently, DNA-protein
complexes were separated from unbound oligonucle-
otides on a pre-electrophorized 6% polyacrylamide gel
and electrotransferred to positively charged nylon mem-
branes (Roche, Dyn Diagnostics Israel). The DNA-protein
complexes were fixed by baking 30 min at 120°C. Bands
were detected with anti-digoxigenin-AP antibody and the
chemiluminescent substrate CSPD (both Roche, Basel,
Switzerland) on X-ray film. Sequence specificity of nuclear
protein-oligonucleotide interaction was confirmed by
competition with cold oligonucleotide and by the addi-
tion of 100 μm PKA inhibitor H89 (Sigma, St. Louis, MO,
USA) to the culture media. For supershift detection, 1 μl
antibody (200 μg/0.1 ml) was added to nuclear extract
mix and incubated for 30 min at 4°C before incubation
with oligonucleotides, and a 4.5% polyacrylamide gel was
used for separation. Antibodies used for supershift are
listed under western blot.
Western blot analysis
Equal amounts of nuclear (according to Bradford assay)
and molecular mass marker were denatured and subjected
to a 10% SDS-polyacrylamide gel electrophoresis. Pro-
teins were electrotransferred to 0.45 μm nitrocellulose
membranes (Scheicher & Schuel, Dassel, Germany). Non-
specific binding was blocked overnight with 20% non-fat
milk and Tris-buffered saline, containing 0.01% Tween-
20. The membranes were incubated for 1 h with 1:2000
primary antibody, washed and incubated for 1 h with
appropriate horseradish peroxidase-conjugated secondary
antibody, then detected by chemiluminescence (ECL;
Beit-Ha'Emek, Israel). The bands were quantified using a
densitometer system endowed with BioCapt and TINA
software (Raytest, Staubenhardt, Germany). Primary anti-
bodies used: Ets-1, Ets-2, Elk-1, Net, PEA3, Erg 1/2/3, C/
EBP α, C/EBP β, C/EBP γ, C/EBP λ, C/EBP ε, p53, phos-
pho-p53 (Ser 392 phosphorylated p53), AP-2α, Ap-2β,
AP-2γ (Santa Cruz, Biotech, California, USA).
Transient transfection of antisense against Ets-2 or p53
JAR cells (5 × 105 per well) were plated on 24-well plates
and transfected in duplicates with 750 nmol/liter anti-
sense against humanEts2 (5'-/FAM/TTC CTT CCC ACC
CTC CTA CC-3') or p53 (5'-/FAM/TCC GTC CCA GTA
GAT TAC CAC-3) (IDT Inc., Hy-labs, Israel) in Optimem
medium (Gibco, Invitrogen, Dorset, UK) using Lipo-
fectamine (Invitrogen, Dorset, UK), according to manu-
facturer's protocol. After 6 hours, media with 20% serum
was added to transfection media. After 24 hours post-
transfection, cells were incubated in 10% FCS for 6 h and
then plated for the various experiments. A reduction of at
least 50% in Ets-2 or p53 distribution was considered a
successful transfection.
Immuno-fluorescence staining
JAR cells or 1st trimester trophoblasts were cultured on
glass coverslips in 35 μl medium drops under mineral oil.
Cells were washed with PBS and fixed with 3.7% Parafor-
maldehyde (Electron Microscope Sciences, Belgar) in PBS
for 10 minutes at 4°C, then washed twice with PBS and
permeabilized for 5 minutes at 4°C with 0.1% Triton
(Sigma, St. Louis, MO, USA) in PBS. Slides were incubated
for 1 hour with blocking buffer 3% BSA-PBS), washed 3
times with PBS and incubated for 30 minutes at room
temperature with 1 μg primary antibodies (Anti MMP-2,
Anti Ets-2, Anti p53). Slides were rinsed five times with
PBS, then incubated for 30 minutes with 0.5 μg secondary
antibody (for F-actin:phalloidin, AlexaFlour-488, A-
12379; for Ets-2 and p53: goat anti-rabbit IgG conjugated
with AlexaFlour-546; for MMP-2: goat-anti mouse IgG
conjugated with AlexaFlour-633, all from Molecular
Probes, Invitrogen, Dorset, UK). Stained cells were photo-
graphed using a confocal microscope (Bio-Rad radiance
2000 confocal set-up with a fluorescent microscope
Nikon E600 with a 60× lens). The photos were analyzed
by Image Pro software (Media Cybernetics, Bethesda,
USA), which quantifies density per area.
Statistical methods
All data are expressed as mean ± SEM. Statistical analysis
of the data was performed using Student's t-test. P < 0.05
was considered significant.
Table 1: Commercial consensus oligonucleotide sequences (Santa Cruz)
Oligonucleotide Catalog No. Consensus binding motif
Ap-1 Sc-2501 5' TGACTCA 3'
Ap-2 Sc-2513 5' GCCCGCGG 3'
C/EBP Sc-2525 5' TTGCGCAA 3'
p53 Sc-2579 5' GAACATGTCTAAGCATGCTG 3'
CREB Sc-2504 5' TGACGTCA 3'
SP-1 Sc-2502 5' GGGGCGGGGG 3'
Ets Sc-2555 5' CAGGAAGT 3'
NFkB Sc-2505 5' GGGGACTTTCCC 3'Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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Results
The effect of forskolin on MMP-2 expression in JAR and 6-
8 w trophoblast
In order to explore the effect of Forskolin upon MMP-2
expression in JAR cells both Northern blot and RT-PCR
was performed using the same RNA samples. In order to
compare the results of the cell-line with primary cells RT-
PCR was performed with 6-8 w 1st trimester trophoblast.
Forskolin was added to JAR or 6-8 w trophoblast culture
for various length of time, in order to find the optimal
exposure. Figure 1 summarizes the results. The mRNA of
MMP-2 was increased in JAR cells by Forskolin (10 μM),
reaching a maximum after 24 hours of incubation (382%
± 60, P = 0.02, Fig. 1A, 363% ± 90, P = 0.03, Fig. 1B). In
6-8 w trophoblast a maximum was reached within 1 hour
after adding Forskolin (147% ± 17, P = 0.03, Fig. 1C).
These exposures were chosen for further studies as opti-
mal exposure for MMP-2 induction.
Effect of forskolin on JAR nuclear protein binding to 
oligonucleotides sequences resembling binding sites found 
in the MMP-2 promoter
In order to detect transcription factors possibly involved
in cAMP induction of MMP-2 in trophoblasts, we per-
formed Gelshift assay (EMSA) of nuclear extract obtained
from cells cultured for 24 hours in the presence or absence
Effect of forskolin on MMP-2 expression in JAR and 6-8 w trophoblast Figure 1
Effect of forskolin on MMP-2 expression in JAR and 6-8 w trophoblast. Top panel, total RNA of MMP-2 isolated form 
JAR (A+B) or 6-8 w trophoblast (C) cultured with Forskolin (10 μM) for the indicated times was assessed by Northern blot 
(A) and semiquantitative reverse transcription-PCR (B+C). Bottom panel, band intensities were quantified with Densitometer 
system endowed with TINA software and the data presented as the ratio of MMP-2 to GAPDH (percent of control). The value 
represents the mean ± SEM from six different experiments performed in duplicates.Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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of 10 μM Forskolin. The binding of nuclear proteins to
labeled oligonucleotides (Table 1), with sequences resem-
bling binding sites found in the MMP-2 promoter, was
explored. This method has been commonly used to detect
possible binding sites and factors involved in transcrip-
tional regulation [27-29]; Figure 2 summarizes the results.
Forskolin increased binding to ETS, C/EBP, AP-2 and p53
DNA binding sites (Fig. 2A). No increase was found in
binding to oligonucleotides SP-1, NFkB, AP-1 and CREB
(data not shown). In order to assure binding specificity,
competing non-labeled 8x excess oligonucleotide was
added to reaction mixture. The non-labeled excess oligo-
nucleotide strongly reduced the gelshift band, hereby
ensuring binding specificity. Additionally, in order to
assure involvement of the PKA signaling pathway, specific
PKA inhibitor H89 (100 μm) was added to cell culture
and gelshift performed (Fig 2B). H89 reduced binding
activity and thereby confirmed the involvement of the
PKA pathway (lane 3, 6, 9, 12).
Identification of transcription factors binding to 
oligonucleotides involved in forskolin- induced MMP-2 
expression
In order to explore transcription factors involved in For-
skolin-induced MMP-2 expression, supershift EMSA was
performed. In this assay, antibodies that recognize and
identify the specific protein, bind to the protein-oligonu-
cleotide complex, resulting in a higher, heavier band. Spe-
cific antibodies belonging to the families of transcription
factors capable of binding to the relevant oligonucleotides
were added to nuclear extract, prior to the binding reac-
tion with oligonucleotides. Figure 2C shows the results.
Antibodies to phospho- p53 (lane 2), to Ets-2 (lane 4), to
Ap-2α (lane 6) and to C/EBPλ (lane 8) and C/EBPε (lane
10) supershifted the EMSA complex in Forskolin-treated
cells. No supershift was found with other members of the
various transcription factor families: ETS-1, Elk-1, Net,
PEA3, Erg 1/2/3 (ETS); C/EBPα, c/EBPβ, C/EBPγ (C/EBP);
p53 (p53); AP-2β, AP-2γ (AP-2) (data not shown).
Detection of transcription factors induced by forskolin and possibly 
involved in MMP-2 regulation
EMSA can only show which transcription factors perform
increased binding to their respective binding sequence
under stimulation of Forskolin but not whether these fac-
tors indeed bind to the MMP-2 promoter. In order to fur-
ther verify our results we performed a complementary
study, using western blot to detect transcription factors
increased in the nucleus by Forskolin. Nuclear cell extract
was prepared from JAR cells cultured 24 hours in the pres-
ence or absence of 10 μM Forskolin and western blot per-
formed with antibodies against the same transcription
factors previous tested with EMSA. Figure 3 shows the
results. Forskolin increased significantly nuclear expres-
sion of AP-2 by 123% ± 11, P = 0.043 (Fig. 3A), of C/EBPε
by 150% ± 24, P = 0.049 (Fig. 4B), of C/EBPλ by 159% ±
22, P = 0.007 (Fig. 3B), of phospho-p53 by 169% ± 34, P
= 0.021 (Fig. 3C) and of Ets-2 by 151% ± 22, P = 0.03 (Fig.
3D).
Of the 5 different transcription factors Ets-2, phospho-
p53, Ap-2α, C/EBPε and C/EBPγ, shown to be increased
by Forskolin, Ets-2 and p53 were chosen for further study
of their contribution to MMP-2 transcriptional regulation
in trophoblasts. Both Ets-2 and p53 have previously been
suggested to be involved in the implantation process [30-
34].
Involvement of Ets-2 in forskolin- induced MMP-2 
expression and trophoblast invasiveness
In order to further examine the involvement of Ets-2 in
Forskolin- induced MMP-2 transcriptional regulation, we
performed a silencing study using antisense against Ets-2.
Ets-2 was inhibited by transfection of JAR cells with a spe-
cific antisense against Ets-2. Cells were then cultured in
the absence or presence of Forskolin and four different
parameters were analyzed. Figure 4A-F shows the results.
Fluorescent antibody staining against Ets-2 and western
blot analysis confirmed the inhibitory effect of the anti-
sense. The transient transfection with Ets-2 antisense
caused a 49% decrease in Ets-2 expression in non treated
cells (100% vs.51% ± 8, P < 0.05), and a 65% decrease in
Forskolin-treated cells (139% vs. 74% ± 6, P < 0.05) (Fig.
4A, B, C).
The inhibition of Ets-2 did not significantly affect the For-
skolin-induced expression of MMP-2 as assessed by RT-
PCR (216% vs.200% ± 10, not significantly) (Fig. 4D).
However, a significantly 47% decrease in MMP-2 secre-
tion in transfected cells, compared with non-transfected
cells, both Forskolin-treated, was found by zymography
(166% vs. 119% ± 9, P < 0.05) (Fig. 4E). In addition Ets-
2 inhibition caused a 52% decrease in trophoblast inva-
siveness, compared with non-transfected cells, both cul-
tured with Forskolin (144% vs. 92% ± 6, P < 0.05) (Fig.
4F).
Involvement of p53 in forskolin- induced MMP-2 
expression and trophoblast invasiveness
JAR cell were transfected with specific antisense against
p53, cultured in the presence or absence of Forskolin and
experiments of four parameters performed. Figure 5
shows the result. The transient transfection with p53 anti-
sense decreased p53 expression by 48% in control cells
(100% vs. 52% ± 11, P < 0.05) and by 85% in Forskolin-
treated cells (150% vs. 65% ± 18, P < 0.05) (Fig. 5A, C).
The inhibition of p53 decreased the Forskolin-induced
expression of MMP-2 by 85%, compared to non-trans-
fected cells, as assessed with immunofluorescent staining
(273% vs. 103% ± 37, P < 0.05) (Fig. 5B, C) and by 146%Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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Effect of forskolin on JAR nuclear protein binding to oligonucleotides corresponding to MMP-2 promoter binding sites Figure 2
Effect of forskolin on JAR nuclear protein binding to oligonucleotides corresponding to MMP-2 promoter bind-
ing sites. A, binding of nuclear proteins, extracted from JAR cells cultured with or without Forskolin (10 μM), to dig-labeled 
oligonucleotides corresponding to consensus binding sites in the MMP-2 promoter was assessed with EMSA. The specificity of 
the DNA-protein complexes was tested by competing with a 8-fold excess unlabeled probe (lane 4, 8, 12, 16) The pictures are 
representative results of twelve different experiments. B, binding of nuclear proteins extracted from JAR cells treated with or 
without Forskolin (10 μM) and in the presence or absence of PKA inhibitor H89 to dig-labeled oligonucleotides was assessed 
with EMSA. The pictures are representative results of five different experiments. C, Specific antibodies against relevant tran-
scription factors were added to the reaction mixture and EMSA supershift assay performed to detect transcription factors 
binding to the complex of dig-labeled oligonucleotides and nuclear proteins from JAR cells cultured with 10 μM Forskolin. 
Lane 1-2, addition of phosho-p53 (pp53) antibody to cell extract. Lane 3-4, Addition of Ets-2 antibody. Lane 5-6, Addition 
of Ap-2α antibody. Lane 7-8, Addition of C/EBPλ antibody and lane 9-10, addition of C/EBPε antibody to cells treated with 
Forskolin. Supershifted bands are designated with an asterisk (*). This result is representative of seven different experiments.Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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as assessed with RT-PCR (283% vs. 137% ± 21, P < 0.05)
(Fig. 5E). This result shows that p53 transcription factor is
involved in MMP-2 transregulation by Forskolin. p53
inhibition also reduced MMP-2 expression in control cells
without Forskolin by 29% (RT-PCR) (100% vs. 71% ± 10,
P < 0.05) or by 47% (immunostaining) (100% vs. 53% ±
15, P < 0.05) (Fig. 5E, C). This indicates that the p53 tran-
scription factor is also involved in the constitutive expres-
sion of MMP-2. A correspondingly decrease in MMP-2
secretion was found by zymography in both groups (Fig.
5F): a 69% decrease in the presence of Forskolin (171%
vs. 102 ± 23, P < 0.05) and a 18% decrease without For-
skolin (100% vs. 82% ± 9, P < 0.05). In addition, p53
inhibition caused a 61% decrease in trophoblast invasive-
ness, compared with non-transfected cells, both cultured
with Forskolin (190% vs. 129% ± 12, P < 0.05) (Fig. 5G).
The effect of forskolin on Ets-2 and p53 in 6-8 w 1st 
trimester trophoblasts - verification of similarity with cell-
line results
Trophoblast cell-lines are excellent models for studying
the mechanism of implantation, but results should always
be verified with primary cells. We therefore performed
EMSA and immunofluorescent staining of Forskolin-
treated 6-8 w 1st trimester trophoblastic cells in order to
verify the presence and involvement of Ets-2 and p53 in
these primary cells. 6-8 w 1st trimester trophoblast were
cultured in the presence or absence of 10 μM Forskolin,
then cells were fixed and stained with fluorescent antibod-
ies against Ets-2, p53 and MMP-2, or total nuclear protein
was extracted and EMSA performed with oligonucleotides
Ets and p53. Figure 6 summarizes the results. Forskolin
increased Ets-2, p53 and MMP-2 expression significantly
by 164 ± 7, 125 ± 12 and 162 ± 13, respectively (Fig. 6A,
B), and increased binding activity to oligonucleotides p53
and Ets in 6-8 w 1st trimester trophoblasts, like previously
found with JAR cells (Fig. 6C). This confirms the resem-
blance between 6-8 w 1st trimester trophoblast and JAR
cells and indicates that the results obtained with JAR cell-
line may be assumed to apply to early trophoblast with
regards of gelatinolytic activity, regulation and invasive-
ness.
Discussion
We have found that Forskolin increases both trophoblast
MMP-2 activity and MMP-2 mRNA expression. The maxi-
mal mRNA response in JAR cells appeared only after 24
hours of incubation, suggesting that Forskolin may stim-
ulate MMP-2 by inducing other, early response genes. The
MMP-9 gene has similarly been reported to be induced
within 24 h in trophoblasts by 12-O-tetradecanoyl phor-
bol 13-acetate (TPA) and TNF, through transcription of
early response genes [29]. In 6-8 w trophoblasts, in con-
trast, Forskolin induced MMP-2 mRNA within 1 h, indi-
cating that Forskolin apparently can stimulate MMP-2
expression more directly, probably through initiating
phosphorylation and migration of already present tran-
scription factors. The controversy found here between JAR
cells and 6-8 w trophoblasts, in regards of time for maxi-
mal mRNA response to Forskolin, underlines that some
differences are to be expected between primary cells and a
cell-line. One can speculate that in choriocarcinoma cells
like JAR, an altered presence of transcription factors or
activation of phosphorylation cascades may be part of the
malignancy of these cells. The difference observed in ulti-
mate magnitude between JAR cells and 1st trimester tro-
phoblasts in response to Forskolin is consistent with our
previous findings, showing the invasive choriocarcinoma
cell-line to be highly expressing MMP-2, both in response
to Forskolin and EGF [8]. The primary trophoblast are less
invasive and express less MMP-2 than the JAR cells.
Forskolin increased the binding of nuclear proteins to oli-
gonucleotides corresponding to the consensus sequence
of AP-2, C/EBP, p53 and Ets response elements in the
MMP-2 promoter. These binding activities were induced
specifically through PKA, since specific PKA- inhibitor
H89 reduced this effect. The supershift EMSA assay
revealed, that transcription factors AP-2α, phospho- p53,
Ets-2 and C/EBPε and -λ bind to their respective binding
sequence under stimulation of Forskolin. Forskolin also
increased the protein expression of Ets-2, C/EBPε, C/EBPλ
and AP-2α, and the phosphorylation of p53 as shown by
western blot. These transcription factors may therefore be
involved in transregulation of the MMP-2 promoter by
Forskolin.
Several transcription factors have been found to be
involved in MMP-2 regulation in various cells, including
AP-2, AP-1 and p53 [28,35,36]. Only a few studies of
MMP-2 transcriptional regulation in trophoblast have
been published, and have focused mainly on the signaling
pathway involved. In 1st trimester trophoblast the MAPK/
Erk1/2 pathway was found to be involved in induction of
MMP-2 and MMP-9 by Cyclosporin A [37]. A cytoplas-
matic tyrosine kinase named focal adhesion kinase was
found to be involved in cell differentiation, adhesion,
proliferation and MMP-2 activity in early trophoblast
[38]. In another study from our lab, progesterone was
found to regulate MMP-2 through differences in proges-
terone-receptor isoforms, apparently by binding to co-
activators or transcription factors, since there is no proges-
terone response element in the MMP-2 promoter [39].
hCG, which like Forskolin acts through PKA, induces
MMP-2 expression and trophoblast invasion through ERK
1/2 and PI3K/AKT pathways [40]. Our study is the first to
focus on transcription factors, which mediate MMP-2
transcriptional regulation in trophoblasts. We chose to
focus our further investigation upon two transcription fac-
tors, Ets-2 and p53, which have previously been suggestedReproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
Page 9 of 15
(page number not for citation purposes)
to be involved in the implantation process. We showed
that that Ets-2 mediates Forskolin-induced MMP-2 activ-
ity, since Forskolin increased Ets-2 expression in trophob-
last and since antisense inhibition of Ets-2 reduced the
Forskolin-induced MMP-2 gelatinolytic activity and tro-
phoblast invasion. Inhibition of Ets-2 did not signifi-
cantly reduce MMP-2 transcription, indicating that this
transcription factor alone, although essential to MMP-2
activity and function, is not sufficient to MMP-2 transcrip-
tional regulation. Based on our results we hypothesize
that Ets-2 may effect MMP-2 regulation on a post-tran-
scriptional level, however further investigation is neces-
sary to elucidate the exact mechanism.
The ETS transcription factor family is characterized by an
highly evolutionary- conserved DNA- binding domain,
that binds to a purine- rich GGA(A/T) core sequence
[41,42]. Ets members direct cytoplasmic signals to control
gene expression and mediate multiple signaling pathways
such as the Ras- Map Kinases, Erk1,2, p38, JNK and the
PI3 kinases, which control their activity, protein partner-
ship and specification of downstream target genes [41-
Detection of transcription factors induced by forskolin in JAR cells Figure 3
Detection of transcription factors induced by forskolin in JAR cells. The expression of various members of transcrip-
tion factor families, capable of binding to AP-2, p53, C/EBP and ETS binding sites, found in the MMP-2 promoter, was examined 
with western blot. JAR cells were cultured in the absence or presence of 10 μM Forskolin and total nuclear proteins extracted. 
Band intensities were quantified with Densitometer system endowed with TINA software and the data represents the mean ± 
SEM from 10 different experiments. Top panel shows representative pictures. Bottom panel - graphs showing quantification of 
bands. The control band intensity was indicated as 100 percent and is represented by black square. Gray square represents 
nuclear extract from Forskolin treated cells. A, AP-2 family; B, C/EBP family; C, p53 family; D, Ets family.Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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43]. Ets members have been shown to interact with sev-
eral transcription factors including AP-1, pit-1, NFkB and
SP-1 [34,42,44]. Ets proteins play important roles in cell
development, differentiation and proliferation, and par-
ticipate in malignancy of tumor cells, including invasion
and metastasis, by activating the transcription of several
cancer-related genes such as proteases and angiogenesis-
related genes [41]. Binding sites for the ETS family are
found in promoters of the MMP family [45], and regula-
tion of matrix degrading proteases by Ets factors in tumor
invasion and metastasis is well established [46]. Ets-2 is
expressed in many cell types in developing mouse
embryos. Targeted deletion of Ets-2 in mice results in
retardation and death of the mouse embryo before 8.5
days of development [34]. These embryos show defects in
the extraembryonic tissue gene expression and function,
including deficient expression of MMP-9, MMP-13 and
MMP-3 and die as a result of trophoblast failure [34,47].
Apparently. Ets-2 is not essential for specifying trophoec-
toderm before the morula-blastocyst transition, since
blastocyst do form and initiate implantation. Properly
Ets-2 coordinates early expression of genes providing full
characteristics to cytotrophoblast, including the produc-
tion of key enzymes and hormones [47]. MMP-2 may be
one of these genes. Ets proteins mediate the control of sev-
eral genes characteristically up-regulated in human tro-
phoblast and involved in trophoblast differentiation and
placenta development [32]. This includes the hCG-α and
hCG-β subunit gene, placental lactogen II, p-450 side
chain cleavage enzyme, decidual/trophoblast prolactin
related gene and MMP-1, -3 [48-51]. The hCG subunits
are activated in stimulation to cAMP through interactions
between Ets and CREB [32,47].
We also found that Forskolin increases p53 expression,
and that p53 mediates Forskolin-induced MMP-2 expres-
sion, gelatinolytic activity and both basic and PKA-
induced trophoblast invasion. In contrast to Ets-2, tran-
Inhibitory effect of Ets-2 antisense upon forskolin-induced MMP-2 expression and secretion and trophoblast invasiveness Figure 4
Inhibitory effect of Ets-2 antisense upon forskolin-induced MMP-2 expression and secretion and trophoblast 
invasiveness. A, JAR cells were transfected with antisense against Ets-2 (As Ets-2), then cultured in the presence or absence 
of 10 μM Forskolin, simultaneously with non-transfected cells, then fixed and stained with a fluorescent antibody against Ets-2 
(A), or nuclear proteins extracted and western blot performed (C). The results are representative photos taking with a confo-
cal microscope, magnification × 60. A-C Results represent 3 different experiments performed in duplicates. B, Density of ETS-
2 staining was quantified with Image software and presented by Bar graph. C, representative pictures of western blot. D, Top 
panel, Total RNA of MMP-2 from JAR cell, with or without treatment with Ets-2 antisense and in the presence or absence of 
Forskolin was assessed by semi-quantitative reverse transcription-PCR. D, Bottom panel, band intensities were quantified with 
Densitometer system and presented as ratio of MMP-2 to GAPDH, as percent of control. Data represents mean ± SEM from 
3 independent experiments performed in quadruples. E, MMP-2 secretion (72 kD) was assessed by zymography of conditioned 
media. E Top panel: Representative zymography gels. E, Bottom panel, Bar graph, representing mean ± SEM from 3 independent 
experiments performed in quadruplets. The control band intensity was indicated as 100 percent. F, Bar graph representing cell 
invasion ability of transfected and non-transfected JAR cells tested with Transwell Invasion Assay from 4 different experiments 
performed in duplicates.Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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sient transfection of antisense mRNA to p53 into trophob-
lasts decreased MMP-2 transcription, both in control and
in Forskolin-treated cells. This indicates, that p53 may be
involved in the constitutive expression of MMP-2, and
additionally mediates the response to PKA. We have
recently published that p53 is involved in MMP-2 regula-
tion and trophoblast invasion by EGF [52]. p53 was
among the transcription factors increased under EGF
stimulation (p53, SP-1, AP-2α and -γ, C/EBPε and-λ). p53
antisense inhibition was found to decrease EGF- induced
MMP-2 mRNA expression, secretion and trophoblast
invasiveness. Together our two studies emphasize the con-
clusion that p53 is involved in MMP-2 regulation in tro-
phoblast. Since AP-2α and C/EBPε and -λ were also
increased by both stimulators, they should be further
examined by functional assays. Other transcription fac-
tors, like ETS-2, may be specific for a certain pathway.
p53 is a 53 kDa nuclear transcription factor, that recog-
nizes and binds to a specific DNA consensus sequence
consisting of two copies of the 10 bp motif 5'-PuPu-
PuC(A/T)(T/A)GPyPyPy-3', separated by 0 to 13 bp [53].
p53 acts as an activator by binding to this sequence and
can also act as a transcriptional repressor of promoters
Inhibitory effect of p53 antisense upon forskolin-induced MMP-2 expression and secretion and trophoblast invasiveness Figure 5
Inhibitory effect of p53 antisense upon forskolin-induced MMP-2 expression and secretion and trophoblast 
invasiveness. JAR cells were transfected with antisense against p53, then cultured in the presence or absence of 10 μM For-
skolin, simultaneously with non-transfected cells. A,B, Representative photos taking with a confocal microscope of JAR cells, 
magnification × 60. JAR cells were fixed and stained with a fluoroscent antibody against p53 (A) or against MMP-2 (B), or 
nuclear proteins extracted and western blot performed (D). A-D Results represent 3 different experiments performed in 
duplicates. C, Density of p53 and MMP-2 staining was quantified with Image software and presented by Bar graph, black-p53, 
grey-MMP-2.D, representative pictures of western blot.ETop panel, Total RNA of MMP-2 from JAR cell, with or without treat-
ment with Ets-2 antisense and in the presence or absence of Forskolin was assessed by semiquantative reverse transcription-
PCR.E, Bottom panel, band intensities were quantified with Densitometer system and presented as ratio of MMP-2 to GAPDH, 
as percent of control. Data represents mean ± SEM from 4 independent experiments performed in duplicates. F, MMP-2 secre-
tion (72 kD) was assessed by zymography of conditioned media. F, Top panel: Representative zymography gels. F, Bottom panel, 
Bar graph, representing mean ± SEM from 3 independent experiments performed in quadruplets. The control band intensity 
was indicated as 100 percent. G, Bar graph representing cell invasion ability of transfected and non-transfected JAR cells tested 
with Transwell Invasion Assay from 3 different experiments performed in quadruplets.Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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lacking a p53 binding site [54-56]. p53 activates genes
involved in DNA repair [30]. Biologically p53 induces G1
arrest and apoptosis following DNA damage [57], and is
therefore known as a common tumor suppressor [58].
Many p53 functions are mediated through the activation
or repression of a series of genes, and this includes the
MMP-2 gene [36]. Mutation of p53 may inactivate the
growth regulatory function and cause a loss of tumor-sup-
pressive activity [59]. Mutation at the specific DNA bind-
ing domain have been identified in nearly 50% of all
human cancers [60]. p53 is present in the preimplanta-
tion human embryo [61,62], and is expressed throughout
mouse implantation development. The p38 MAPK path-
way was found to regulate p53 expression in 2-8 cell
mouse embryos [63]. p53-deficient mice are viable and
reproductive, however in p53- null (p53(-/-) the placenta
The effect of forskolin on Ets-2 and p53 expression in 6-8 w 1st trimester trophoblasts Figure 6
The effect of forskolin on Ets-2 and p53 expression in 6-8 w 1st trimester trophoblasts. A, Representative photos 
taking with a confocal microscope of 6-8 w 1st trimester trophoblast, magnification × 60. 6-8 w 1st trimester trophoblast, cul-
tured with or without Forskolin (10 μM), were fixed and stained with a fluorescent antibody against Ets-2, p53 or MMP-2. B, 
Density of p53, Ets-2 and MMP-2 staining was quantified with Image software and presented by Bar graph, left-Ets-2, middle-
p53, right-MMP-2. C, Binding of nuclear proteins extracted from 6-8 w 1st trimester trophoblast cells treated with or without 
Forskolin (10 μM) to dig-labeled oligonucleotides Ets and p53 was assessed with EMSA. Results represent 2 different experi-
ments performed in triplicates.Reproductive Biology and Endocrinology 2009, 7:135 http://www.rbej.com/content/7/1/135
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is altered [64]. In rodent placenta, a decrease in p53 is part
of the transition of trophoblast from a state of prolifera-
tion to differentiation in trophoblast [33]. p53 has a short
half-live, and is therefore normally present at very low
concentrations in cells [30]. However, p53 is detectable in
the nucleus and cytoplasm of cytotrophoblasts and syncy-
tiotrophoblasts [30,65,66], and this apparently overex-
pression of p53 in trophoblasts may be controlling
excessive proliferation in normal placentation [67]. It
appears that most p53 protein forms complexes in the
cytoplasm and tetramers in the nuclei in cytotrophoblasts,
suggested to stabilize p53 and hereby prolong the half-life
[30,31]. p53 is correlated with enhanced apoptosis in tro-
phoblast [68], and can be induced by hypoxia [69].
Increased p53 and apoptosis was found in different preg-
nancy complications, such as preeclampsia [69,70], fetal
growth restriction [68] and Gestational Trophoblastic dis-
eases (GTDs) [71]. In invasive hydatidiform moles, char-
acterized by abnormal growth of chorionic tissues with
various degrees of local invasion and metastasis, MMP-2
and mutant p53, but not wild type p53 (wtp53), were
increased, as compared to normal placenta, and may be
involved in this pathology [72]. However, since mutant
p53 may still perform normal suppressive activity,
depending on the localization of the mutation, and since
other reports found wtp53 to be elevated in hydatidiform
moles [73-75], the role of wtp53 in this pathology is not
clear. A recent article described that exogenous p53, but
not endogenous p53, decrease MMP-9 in cytotrophob-
lasts [76]. In their report, in contrast to our results, p53
inhibition had no effect on either MMP-2 or MMP-9, and
the authors suggested that p53 is inactivated in trophob-
lasts, maybe through formation of high molecular weight
complexes. These controversial results regarding MMP-2
may result from differences in experimental design,
including the use of JAR cells as a model as well as primary
trophoblast of different gestational ages (early versus late
1st trimester trophoblast).
The examined transcription factors in this study are
involved in transactivation and transrepression of many
genes, thus the EMSA does not allow us to conclude, that
MMP-2 is one of them. However, the studies using trans-
fection of p53 and Ets-2 antisense in JAR demonstrate that
at least p53 is involved in Forskolin-induced MMP-2
expression, while Ets-2 may effect post-transcriptional
regulation. Our results suggest that MMP-2 regulation in
trophoblast is mediated by several transcription factors,
including p53 and Ets-2, however since MMP-2 transcrip-
tion, secretion and trophoblast invasion were not com-
pletely diminished, other transcription factors must be
involved. This may include C/EBP-ε, C/EBPλ and AP-2α,
which should be subject to further study.
Conclusion
MMP-2 regulation by PKA is mediated through several
binding sites and transcription factors including Ets-2,
p53, C/EBPε, C/EBPλ and AP-2α. Ets-2 and p53 mediate
PKA- induced trophoblast invasiveness through regula-
tion of MMP-2 expression and activity.
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